SCHEMBL680906

SCHEMBL680906

CCOC(=O)c1cc(CN2CCOCC2)cn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
LMNA P02545 3/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TSHR P16473 2/20 0.45
MAPK1 P28482 1/20 0.45
STAT3 P40763 1/20 0.45
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
NPC1 O15118 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
THRB P10828 1/20 0.41
CMA1 P23946 1/20 0.40
ENPP2 Q13822 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679107 0.85 NPC1 (0.46) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL17896908 0.81 GRM2 (0.57) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL680604 0.78 ALDH1A1 (0.52) ALDH1A1LMNARAB9AMAPTMAPK1
SCHEMBL6709588 0.73 ALDH1A1 (0.51) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL6712622 0.73 HTT (0.52) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL146852 0.73 TSHR (0.55) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL679238 0.73 NPSR1 (0.46) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL18375622 0.72 TSHR (0.60) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL6724133 0.72 ALDH1A1 (0.44) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL6709410 0.72 NPC1 (0.48) ALDH1A1LMNARAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC ALDH1A1 1450/4885LMNA 4448/4885RAB9A 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.